Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Health Serv Outcomes Res Methodol. 2020 Sep 10;21:169–187. doi: 10.1007/s10742-020-00219-3

Table 5:

Characteristics of patients in the Flatiron Health mUC cohort by treatment type.

Carboplatin-Based Chemotherapy Immunotherapy

N = 1600 N = 587
Age, mean (SD) 72.56 (8.48) 74.74 (8.75)

Gender, N (% Male) 1171 (73.2) 427 (72.7)

Race/Ethnicity N (%) White 1213 (75.8) 437 (74.4)
Asian 23 (1.4) 4 (0.7)
Black or African American 75 (4.7) 21 (3.6)
Hispanic or Latino 71 (4.4) 23 (3.9)
Other Race 99 (6.2) 35 (6.0)
Unknown 119 (7.4) 67 (11.4)

Baseline Year N (%) 2011 110 (6.9) 0 (0.0)
2012 165 (10.3) 0 (0.0)
2013 224 (14.0) 0 (0.0)
2014 238 (14.9) 0 (0.0)
2015 283 (17.7) 8 (1.4)
2016 308 (19.2) 101 (17.2)
2017 195 (12.2) 283 (48.2)
2018 77 (4.8) 195 (33.2)

Primary Site N (%) Bladder 1185 (74.1) 444 (75.6)
Renal Pelvis 263 (16.4) 75 (12.8)
Ureter 140 (8.8) 65 (11.1)
Urethra 12 (0.8) 3 (0.5)

Smoking Status N (%) History of smoking 1145 (71.6) 434 (73.9)
No history of smoking 419 (26.2) 147 (25.0)
Unknown/not documented 36 (2.2) 6 (1.0)

1 year comorbidity score, mean (SD) 0.90 (2.67) 1.86 (4.03)